Profile 1: Personal or Family History of Medullary Thyroid Carcinoma or MEN2 The FDA-approved prescribing information for semaglutide injection (Ozempic, Wegovy) carries a boxed warning: semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
Semaglutide is an active ingredient in Wegovy, Ozempic, and Rybelsus
This challenge appears consistently during dose increases and when rotation slips, and in people with sensitive skin, it often ties to sensitivity to an inactive ingredient or repeated needle trauma
My work focuses on evidence-based obesity care, including nutrition therapy, behavior change support, and clinical guidance for patients using incretin-based therapies
The pathophysiology involves multiple mechanisms, including metabolic disturbances from chronic hyperglycaemia, oxidative stress, inflammation, and microvascular insufficiency that compromises nerve blood supply